← Back to patent-cliff list
NNC0480-0389
Tier C — Watch / tradeNNC0480-0389
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：GIPR, GLP1R
Indications (approved)：Type 2 diabetes, Overweight, Obesity
Regional status
US
Phase II
2021-11-29
EU
Phase II
2021-11-29
China
Phase I
2022-08-11
Japan
Phase II
2021-11-29
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NNC0480-0389?
Approved indications include: Type 2 diabetes, Overweight, Obesity.
When does the NNC0480-0389 patent expire?
No public expiry year is available for NNC0480-0389 yet; this page updates once verified.
How do I get a quote for NNC0480-0389 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21